As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.» Read More
NEW YORK— Shares of some top drug benefits companies are down at 10 a.m.:. CVS Health Corp. fell $1.10 or 1.1 percent, to $100.07. Express Scripts Holding Co. fell$. 81 or. 9 percent, to $85.56.
NEW YORK— Shares of some top drug benefits companies were down at the close of trading:. CVS Health Corp. fell$. 56 or. 6 percent, to $101.17. Express Scripts Holding Co. fell$. 69 or. 8 percent, to $86.37.
NEW YORK— Shares of some top drug benefits companies are down at 1 p.m.:. CVS Health Corp. fell$. 59 or. 6 percent, to $101.14. Express Scripts Holding Co. fell$. 72 or. 8 percent, to $86.34.
NEW YORK— Shares of some top drug benefits companies were down at the close of trading:. CVS Health Corp. fell$. 38 or. 4 percent, to $101.73. Express Scripts Holding Co. fell $1.00 or 1.1 percent, to $87.06.
NEW YORK— Shares of some top drug benefits companies are down at 1 p.m.:. CVS Health Corp. fell$. 38 or. 4 percent, to $101.73. Express Scripts Holding Co. fell$. 77 or. 9 percent, to $87.29.
NEW YORK, March 30- UnitedHealth Group Inc's planned takeover of No. 4 U.S. pharmacy benefits provider Catamaran Corp will give the companies added heft in price talks with drug companies, serving as a catalyst for deals allowing other insurers to bulk up. The $12.8 billion deal comes at a time when Wall Street has been parsing the possibilities that top insurers...
An analysis of about 4,500 patients who stayed on treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of those given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group on standard treatment, which ranged from diet changes to...
Here are the stocks to watch heading out of this weekend's American College of Cardiology conference in San Diego.
Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.
WASHINGTON, March 11- The entry of copycat biotech drugs into the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, depending on the level of competition among drugmakers, a top executive at CVS Health Corp told Reuters. CVS is one of the largest U.S. pharmacy benefit managers and, along with rival Express Scripts, has put...
Spending on prescription drugs in the U.S. rose 13.1% in 2014, the biggest increase in more than a decade, according a report from Express Scripts.
*FDA set to decide on approval of Novartis' Zarxio. LONDON/ LOS ANGELES, March 6- A revolution is brewing in healthcare with lower-cost copies of complex biotech drugs finally set to reach the United States, nine years after so-called biosimilars were launched in Europe. The first approval for a biosimilar in the United States is expected imminently- Zarxio,...
The "Halftime Report" traders give their final trades of the show.
As investors await word on U.S. interest rate increases, quantitative easing certainly seems to be helping stock markets in Europe and Japan.
Some of the names on the move ahead of the open.
Check out which companies are making headlines after the bell Monday: Stifel, Express Scripts, SunPower & more.
U.S. stocks pulled back from Friday's records to close narrowly mixed ahead of Fed Chair Janet Yellen's remarks over the next two days.
U.S. stock index futures signaled a lower open on Monday as uncertainty surrounded Greece's deal with its euro zone creditors.
With the Dow soaring to new highs, Jim Cramer is ready to do some buying in case the euphoria wears off.
U.S. stocks are the place to be right now, Delphi's Scott Black said Friday on CNBC. Here's where he's putting his money.